Alkermes plc (NASDAQ:ALKS) Analyst Rating Consensus

Alkermes plc (NASDAQ:ALKS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.66 by 5 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 1 Analysts have rated it as strong sell.

Other Equity analysts have also commented on the company shares. Evercore ISI Group initiates coverage on Alkermes plc (NASDAQ:ALKS).The analysts at the brokerage house have a current rating of Buy on the shares. The rating by the firm was issued on May 26, 2016.

Alkermes plc (NASDAQ:ALKS): The stock price is expected to reach $ 57.8 in the short term. The number of analysts agreeing with this consensus is 5. The higher estimate for the short term price target is at $77 while the lower estimate is at $50. The standard deviation of the price stands at $11.23.

Alkermes plc (NASDAQ:ALKS) witnessed a decline in the market cap on Tuesday as its shares dropped 0.1% or 0.04 points. After the session commenced at $42.29, the stock reached the higher end at $42.55 while it hit a low of $41.27. With the volume soaring to 926,055 shares, the last trade was called at $41.85. The company has a 52-week high of $80.71. The company has a market cap of $6,326 million and there are 151,165,400 shares in outstanding. The 52-week low of the share price is $27.14.

Alkermes plc has lost 0.33% in the last five trading days and dropped 2.63% in the last 4 weeks. Alkermes plc is up 28.57% in the last 3-month period. Year-to-Date the stock performance stands at -47.28%.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *